Mesothelioma is a serious cancer caused by asbestos exposure. It develops in the lining of lungs (pleural mesothelioma), abdomen (peritoneal), or heart (pericardial). Most cases develop 20-50 years after exposure. Prognosis has been poor historically, but newer treatments offer hope.

What Is Mesothelioma?

Mesothelioma arises from mesothelial cells that line the lungs, abdomen, and other organs. Asbestos fibers inhaled or ingested become embedded in these linings, causing chronic inflammation that eventually leads to cancer.

Key fact: There is no safe level of asbestos exposure, though latency period and fiber type affect risk.

Types

  • Pleural mesothelioma: Most common (75% of cases). Develops in lung lining. Causes chest pain, cough, pleural effusion.
  • Peritoneal mesothelioma: Develops in abdominal lining. Causes abdominal pain and swelling.
  • Pericardial mesothelioma: Rare. Develops in heart sac lining. Can cause cardiac arrhythmias and tamponade.

Asbestos Exposure

High-risk occupations: Construction, shipbuilding, military service, automotive repair, insulation work, firefighting.

Secondary exposure: Family members exposed to asbestos dust brought home on contaminated clothing.

Latency: 20-50 years typically elapse between exposure and disease onset.

Symptoms

Pleural mesothelioma:

  • Chest pain or pressure
  • Persistent cough
  • Shortness of breath
  • Pleural effusion (fluid around lungs)

Peritoneal mesothelioma:

  • Abdominal pain and swelling
  • Nausea and vomiting
  • Bowel obstruction
  • Ascites (abdominal fluid)

Diagnosis

Diagnostic tools:

  • Imaging: Chest X-ray, CT scan showing pleural thickening, nodularity, or effusion.
  • Biopsy: Thoracentesis (fluid drainage) or pleural biopsy for pathologic confirmation. Immunohistochemistry helps differentiate mesothelioma from adenocarcinoma.
  • PET scan: Staging to check for metastases.

Staging

Uses TNM system adapted for mesothelioma. Four stages based on tumor extent and involvement of adjacent structures. Stage I-II have better prognosis than advanced disease.

Treatment Options

Multimodal Therapy (Surgery + Chemotherapy + Radiation)

Best outcomes achieved with combination approach. Pleurectomy/decortication or extrapleural pneumonectomy removes affected pleura/lung, followed by chemotherapy and radiation.

Surgery

Pleurectomy/decortication (P/D): Removes pleural lining while preserving lung. Less morbid than pneumonectomy.

Extrapleural pneumonectomy (EPP): Removes entire lung, pleura, diaphragm, and pericardium. More extensive but sometimes better for complete resection.

Cytoreduction: For peritoneal mesothelioma, maximum debulking with hyperthermic intraperitoneal chemotherapy (HIPEC).

Chemotherapy

Pemetrexed + cisplatin: Standard chemotherapy regimen. Often combined with bevacizumab (anti-angiogenesis).

Radiation

Focal radiation to tumor site or hemithoracic radiation after surgery to control local disease.

Immunotherapy

Checkpoint inhibitors (nivolumab, pembrolizumab) showing promise in mesothelioma, particularly for refractory disease.

Prognosis

Historically poor, but improving with multimodal therapy:

  • Early-stage with trimodal therapy: Median overall survival 12-18+ months.
  • Advanced disease: Median 8-12 months with chemotherapy alone.
  • Peritoneal with cytoreduction + HIPEC: 5-year survival 30-40% in selected patients.

Seek Immediate Care If You Experience:

  • Severe shortness of breath or chest pain
  • Hemoptysis (coughing up blood)
  • Signs of cardiac tamponade (palpitations, syncope, severe chest pain)

Key Questions for Your Doctor

  • What stage is my mesothelioma?
  • Am I a candidate for multimodal therapy?
  • What surgical approach is recommended?
  • How much chemotherapy will I receive?
  • What are realistic survival expectations?
  • Are there clinical trials available?
  • Do I have legal/compensation options regarding asbestos exposure?